lomitapide lomitapide lomitapide , sold under the brand name juxtapid in the us and lojuxta in the eu, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by aegerion pharmaceuticals. it has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate. lomitapideclinical datatrade namesjuxtapid (us), lojuxta (eu)other namesaegr-773, bms-201038license data eu ema: by inn us dailymed: lomitapide us fda: lomitapide routes ofadministrationby mouthatc codec10ax12 (who) legal statuslegal status us: ℞-only eu: rx-only identifiers iupac name n-(2,2,2-trifluoroethyl)-9-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9h-fluoren-9-carboxamide cas number182431-12-5 ymesylate: 202914-84-9pubchem cid9853053mesylate: 11274333iuphar/bps7439drugbankdb08827 ymesylate: dbsalt000110chemspider8028764 nmesylate: 9449335unii82kub0583fmesylate: x4s83cp54ekeggd09637 ymesylate: d09638chebichebi:72297 nmesylate: chebi:72299chemblchembl354541mesylate: chembl2105662comptox dashboard (epa)dtxsid50171294 chemical and physical dataformulac39h37f6n3o2molar mass693.734 g·mol−13d model (jsmol)interactive image smiles fc(f)(f)c5ccc(cc5)-c1ccccc1c(=o)nc4ccn(cc4)ccccc2(c(=o)ncc(f)(f)f)c3ccccc3-c6ccccc26 inchi inchi=1s/c39h37f6n3o2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28h,7-8,19-25h2,(h,46,50)(h,47,49) nkey:mbbcvakajpkakm-uhfffaoysa-n n ny (what is this?) (verify) the us food and drug administration (fda) approved lomitapide in december 2012, as an orphan drug to reduce ldl cholesterol, total cholesterol, apolipoprotein b, and non-high-density lipoprotein (non-hdl) cholesterol in people with homozygous familial hypercholesterolemia (hofh). in july 2013, the european commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (ldl) apheresis in adults with hofh. mechanism of action lomitapide inhibits the microsomal triglyceride transfer protein (mtp or mttp) which is necessary for very low-density lipoprotein (vldl) assembly and secretion in the liver. in december 2012, drug manufacturer aegerion announced they had been approved by the fda to as "an adjunct to a low-fat diet and other lipid-lowering treatments...in patients with homozygous familial hypercholesterolemia (hofh)." side effects in a phase iii study, lomitapide led to elevated aminotransferase levels and fat accumulation in the liver.